Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κb ligand-induced osteoclastogenesis

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 10, 2012, Pages 886-893

  Gong, Wei ^a   Dou, Huan ^a   Liu, Xianqin ^b   Sun, Lingyun ^b   Hou, Yayi ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Osteoclastogenesis; Receptor activator of nuclear factor B ligand (RANKL); Technetium 99 conjugated with methylene diphosphonate (99Tc MDP)

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; CD51 ANTIGEN; COLONY STIMULATING FACTOR 1; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MEDRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TECHNETIUM 99M; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL LINE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; MACROPHAGE; MOUSE; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; OSTEOCLASTOGENESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ACID PHOSPHATASE; ANIMALS; BONE RESORPTION; CATHEPSIN K; CELL DIFFERENTIATION; CELL LINE; FEMALE; INTEGRIN ALPHAV; INTERLEUKIN-1BETA; INTERLEUKIN-6; ISOENZYMES; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; ONCOGENE PROTEINS V-FOS; OSTEOCLASTS; RADIOPHARMACEUTICALS; RANK LIGAND; TECHNETIUM TC 99M MEDRONATE;

EID: 84866777753     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.12006.x     Document Type: Article

References (49)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-42.
2. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289: 1508-14.
3. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-8.
4. O'Gradaigh D, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis Interactions between tumour necrosis factor α, interleukin 1, and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 2004; 63: 354-9.
5. Meiyanto E, Hoshijima M, Ogawa T, Ishida N, Takeya T. Osteoclast differentiation factor modulates cell cycle machinery and causes a delay in s phase progression in RAW264 cells. Biochem. Biophys. Res. Commun. 2001; 282: 78-83.
6. Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life 2005; 57: 389-95.
7. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 65-76.
8. Xu J, Tan JW, Huang L et al. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J. Bone Miner. Res. 2000; 15: 2178-86.
9. Yonezawa T, Hasegawa S, Asai M et al. Harmine, a beta-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo. Eur. J. Pharmacol. 2011; 650: 511-8.
10. Lee SE, Woo KM, Kim SY et al. The phosphatidylinositol 3-kinase, p38, and extra cellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 2002; 30: 71-7.
11. Yamashita T, Yao Z, Li F et al. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 2007; 282: 18245-53.
12. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 2003; 4: 638-49.
13. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-κB (RANK) Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J. Biol. Chem. 1998; 273: 20551-5.
14. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007; 40: 251-64.
15. Grigoriadis AE, Wang ZQ, Cecchini MG et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination bone remodeling. Science 1994; 266: 443-8.
16. 2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002; 3: 889-901.
17. Li ML, Li MQ, Zhang LZ, Zhang Y, Li M. Inventors. Chengdu Isotope Application Institution (CIAI) of the Nuclear Power Institute of China, assignee. Drug used in the treatment of rheumatoid arthritis. Chinese patent no. ZL94113006.1. 22 November 1995.
18. 99Tc methylenediphosphonate injection. China. J. Rheumatol. 2003; 12: 752-4.
19. Zhang MM, Liu ZH, Wu NB, Guo Z, Zhang CX, Tang P. The regulation of Yunke in bone metabolism of postmenopausal osteoporosis. China. J. Osteoporos. 2008; 9: 569-70 (in Chinese).
20. Wang CX, Zhang LM. Clinical analysis of ankylosing spondylitis treated with Yunke. J. Taishan Med. Coll. 2007; 8: 640-2 (in Chinese).
21. Liu SJ, Sun ZJ, Zhou YO, Zuo XX. Effect of 99 technetium-methylenediphosphonate on bone erosion in collagen-induced arthritis rats. Int. J. Pathol. Clin. Med. 2010; 2: 124-9.
22. 99Tc-MDP) and/or colloidal chromic phosphate phosphonium-32, alone and in combination, in rats with adjuvant arthritis. Clin. Exp. Pharmacol. Physiol. 2008; 35: 23-8.
23. Karatay S, Erdem T, Yildirim K et al. The effect of individualized diet challenges consisting of allergenic foods on TNF-alpha and IL-1beta levels in patients with rheumatoid arthritis. Rheumatology 2004; 43: 1429-33.
24. Monje P, Hernandez-Losa J, Lyons RJ, Castellone MD, Gutkind JS. Regulation of the transcriptional activity of c-Fos by ERK A novel role for the prolyl isomerase PIN1. J. Biol. Chem. 2005; 280: 35081-4.
25. 99Tc-MDP) inhibits experimental choroidal neovascularization in vivo and VEGF-induced cell migration and tube formation in vitro. Invest. Ophthalmol. Vis. Sci. 2011; 52: 5702-12.
26. Yan SX, Wang Y, Peng GJ, Lu XP, Fu Y. Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with Graves' ophthalmopathy. Nucl. Med. Commun. 2011; 32: 142-6.
27. 99Tc methylenediphosphonate inhibits osteoclast formation from PBMCs in patients with rheumatoid arthritis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34: 684-8 (in Chinese).
28. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984; 27: 968-75.
29. Takayanagi H, Oda H, Yamamoto S et al. A new mechanism of bone destruction in rheumatoid arthritis: Synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997; 240: 279-86.
30. Gravallese EM, Manning C, Tsay A et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000; 43: 250-8.
31. Takayanagi H, Iizuka H, Juji T et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000; 43: 259-69.
32. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 2001; 159: 1689-99.
33. Hayashi H, Nakahama K, Sato T et al. The role of Mac-1 (CD11b/CD18) in osteoclast differentiation induced by receptor activator of nuclear factor-kappaB ligand. FEBS Lett. 2008; 582: 3243-8.
34. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999; 20: 345-57.
35. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 1998; 95: 3597-602.
36. Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Redini F. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Exp. Cell Res. 2004; 293: 292-301.
37. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 2000; 275: 31155-61.
38. Mizukami J, Takaesu G, Akatsuka H et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB 2, and TRAF6. Mol. Cell. Biol. 2002; 22: 992-1000.
39. Hotokezaka H, Sakai E, Kanaoka K et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J. Biol. Chem. 2002; 277: 47 366-72.
40. Jang YJ, Kim ME, Ko SY. n-Butanol extracts of Panax notoginseng suppress LPS-induced MMP-2 expression in periodontal ligament fibroblasts inhibit osteoclastogenesis by suppressing MAPK in LPS-activated RAW264.7 cells. Arch. Oral Biol. 2011; 56: 1319-27.
41. Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc. Res. Tech. 2003; 61: 504-13.
42. Tezuka K, Tezuka Y, Maejima A et al. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 1994; 269: 1106-9.
43. 99Tc-MDP and its role in proinflammatory cytokines in rheumatoid arthritis. China. J. Rheumatol. 2004; 8: 39-41.
44. Takayanagi H. Osteoimmunology. Shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007; 7: 292-304.
45. Nakashima T, Takayanagi H. Osteoimmunology: Crosstalk between the immune and bone systems. J. Clin. Immunol. 2009; 29: 555-67.
46. Matsuo K, Galson DL, Zhao C et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J. Biol. Chem. 2004; 279: 26475-80.
47. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol. Rev. 2005; 208: 126-40.
48. Ang ES, Pavlos NJ, Chim SM et al. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-kappaB and ERK. J. Cell. Biochem. 2012; 113: 946-55.
49. Ang ES, Yang X, Chen H, Liu Q, Zheng MH, Xu J. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-kappaB and ERK activation. FEBS Lett. 2011; 585: 2755-62.